Lein Applied Diagnostics, a British company that develops blood glucose measuring for people with diabetes, has announced it has received further investment from its shareholder Seven Spires Investments. The company is seeking more investment to put a non-invasive blood glucose meter into clinical trials.
Micromet AG, a spin-off from the Institute for Immunology at Munich University, said it has agreed to grant four licenses of its single chain antibody technology to Abbott Laboratories, Alligator Bioscience AB, Haptogen Ltd. and an unnamed biopharmaceutical company, for the development of cancer treatments.
Lipoxen Plc, a drug spin-out company from the University of London's School of Pharmacy, said it has raised £3.78 million from a placing of 28 million shares for hiring news staff for preclinical trials to treat diabetes, Pneumococcal infections, and hepatitis C.
Forget stem cells, pharmacogenomics and the next big cure - Michael Kenward gazes into his prophecy book to see what the physical sciences have in store for us this year. Or maybe not.
Scientists at Edinburgh University have developed a new method for cleaning surgical instruments that entirely removes protein contamination, including the near-indestructible prions - the agents that cause mad cow disease
The first investor-ready company has rolled off the production line in a scheme set up by the development agency Yorkshire Forward to commercialise research from the UK county's universities.
Charges of scientific fraud in Korea aren't likely to faze Britain's ambitious stem-cell efforts, as evidenced by plans for a £40 million lab run by the 'father' of Dolly the sheep.
Lab-supply companies are normally in the business of selling things to scientists, rather than buying. But the new CEO of Sigma-Aldrich, one of the world's largest lab-supply firms, is shopping for new ideas, new partners - and new companies to invest in.
"I didn't think they would be at this stage for decades, let alone within a year."
Gerald Schatten, colleague of Korea's stem-cell celebrity, before scandal broke
Sworn enemies within the technology and pharmaceutical industries are joining forces in a lobbying drive to persuade European Union lawmakers to change a draft law they say will stifle innovation in Europe by criminalising patent infringements, along with all forms of intellectual property infringements.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.